Datasets:
NCT ID stringlengths 11 11 | Brief Title stringlengths 18 300 | Official Title stringlengths 26 590 ⌀ | Organization stringlengths 3 107 | Overall Status stringclasses 1
value | Start Date stringlengths 7 10 | Completion Date stringlengths 7 10 ⌀ | Study Type stringclasses 1
value | Phases stringclasses 1
value | Enrollment Count int64 1 358k | Conditions stringlengths 3 1.22k | Keywords stringlengths 2 750 ⌀ | Eligibility Criteria (registry) stringlengths 67 17.4k | Sex stringclasses 3
values | Minimum Age stringclasses 79
values | Maximum Age stringclasses 119
values | Brief Summary stringlengths 38 4.86k | Protocol Doc Count int64 1 6 | Protocol Filenames stringclasses 45
values | Protocol URLs stringlengths 69 424 | SNOMED CT stringlengths 4 82 | primary_therapeutic_area stringclasses 22
values | complete eligibility criteria stringlengths 174 23.3k | Acronym stringlengths 2 14 ⌀ | Primary Completion Date stringlengths 7 10 | Intervention Model stringclasses 5
values | Primary Purpose stringclasses 9
values | Masking stringclasses 5
values | Arms stringlengths 1 1.27k ⌀ | Interventions stringlengths 14 3.84k | Primary Outcomes stringlengths 28 64.1k | Secondary Outcomes stringlengths 33 185k ⌀ | Healthy Volunteers bool 2
classes | Standard Ages stringclasses 6
values | Detailed Description stringlengths 8 26.5k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT03683030 | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR) | Biosense Webster, Inc. | COMPLETED | 2018-10-22 | 2022-02-18 | INTERVENTIONAL | PHASE3 | 397 | Atrial Fibrillation | Interventional, Radiofrequency Ablation, Paroxysmal Atrial Fibrillation | Key Inclusion Criteria:
* Diagnosed with Symptomatic Paroxysmal Atrial Fibrillation.
1. At least two symptomatic AF episodes within last six months from enrollment.
2. At least one ectrocardiographically documented AF episode within twelve (12) months prior to enrollment.
* Failed at least one Class I or Class II... | ALL | 18 Years | 75 Years | The primary objective of this clinical investigation is to demonstrate safety and effectiveness of the Multi-Electrode RF Balloon catheter for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation. | 1 | Prot_004.pdf | https://cdn.clinicaltrials.gov/large-docs/30/NCT03683030/Prot_004.pdf | Atrial fibrillation | Cardiology | Inclusion Criteria:
- Diagnosed with Symptomatic PAF (Physician’s note indicating recurrent self-terminating AF).
- At least two (2) symptomatic AF episodes within last six (6) months from enrollment.
- At least one (1) electrocardiographically documented AF episode within twelve (12) months prior to enrollment. Electr... | STELLAR | 2022-02-18 | SINGLE_GROUP | TREATMENT | NONE | Treatment Group | DEVICE: Multi-Electrode RF Balloon Catheter (Multi-Electrode RF Balloon Catheter will be inserted) | Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter: An AE is any untoward medical occurrence in a participant whether or not related to the investigational medical device. PAEs included myocardial infarc... | Percentage of Participants With Acute Procedural Success: Acute procedural success is defined as confirmation of entrance block in clinically relevant pulmonary veins (PVs) (all PVs except those that were silent and/or could not be cannulated) after adenosine and/or isoproterenol challenge (with or without the use of a... | false | ADULT, OLDER_ADULT | The STELLAR study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the Multi-Electrode RF Balloon catheter. The study will evaluate the safety and effectiveness of the Multi-Electrode RF Balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (PAF). |
NCT02725567 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation | A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation | Vertex Pharmaceuticals Incorporated | COMPLETED | 2016-06-02 | 2022-06-28 | INTERVENTIONAL | PHASE3 | 57 | Cystic Fibrosis | null | Inclusion Criteria:
* Confirmed diagnosis of CF by sweat chloride value or CF mutation criteria.
* Have 1 of the following 10 CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D or R117H (eligible in regions where ivacaftor is approved for use). Part A/B group may als... | ALL | 1 Month | 24 Months | The purpose of this study was to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in participants with cystic fibrosis (CF) who are \<24 months of age at treatment initiation and have an ivacaftor-responsive CF transmembrane conductance regulator (CFTR) gene mutation. | 1 | Prot_000.pdf | https://cdn.clinicaltrials.gov/large-docs/67/NCT02725567/Prot_000.pdf | Cystic fibrosis | Pulmonology | Inclusion Criteria:
- Male or female with confirmed diagnosis of CF, defined as a sweat chloride value ≥60 mmol/L by quantitative pilocarpine iontophoresis OR 2 CF-causing mutations.
- A sweat chloride test must be performed if the sweat chloride value is not available in the subject’s medical records and the value is ... | null | 2022-06-28 | PARALLEL | TREATMENT | NONE | Part A: 3 to <24 months; Part B + A/B:1 to < 24 months | DRUG: IVA (Granules in sachet for oral administration.) | Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs): (Day 1 through Day 70); Part A: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA): (Pre-dose, 2-4 hours, 6-8 hours, 24-60 hours post-dose); Part B +A/B... | Part B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA): (Week 2 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 8 (pre-dose,1 hour, 4-hour post-dose); Week 24 (pre-dose, 2-4 hours post dose)); Part B + A/B: Absolute Change From Baseline in Sweat Chloride: Sweat samples were collected u... | false | CHILD | null |
NCT02135692 | A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects | A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial | GlaxoSmithKline | COMPLETED | 2014-05-29 | 2017-10-05 | INTERVENTIONAL | PHASE3 | 339 | Asthma | Severe eosinophilic asthma, Extension study, Expanded access, Safety, Mepolizumab, Eosinophils | Inclusion Criteria:
* Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent.
* Male or Eligible Female Subjects: To be eligible for the study, females of child-bearing potential must commit to consistent and correct use of an acceptabl... | ALL | 12 Years | null | This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma. This study will enroll a subset of subjects from Study MEA115661 who have demonstrated clear benefit from therapy and who without ... | 1 | Prot_000.pdf | https://cdn.clinicaltrials.gov/large-docs/92/NCT02135692/Prot_000.pdf | Asthma | Pulmonology | Inclusion Criteria:
- Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent.
- Male or Eligible Female Subjects: To be eligible for the study, females of child-bearing potential must commit to consistent and correct use of an acceptable... | null | 2017-10-05 | SINGLE_GROUP | TREATMENT | NONE | Mepolizumab 100 mg | BIOLOGICAL: Mepolizumab (Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.); DRUG: SOC (Standard of Care (SOC) will differ by participant, however it will generally include oral... | Annualized Rate of On-treatment Exacerbations Per Year: Exacerbations are defined as the worsening of asthma which requires use of systemic corticosteroids intravenous (IV) or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic ... | Mean Change From Baseline in Asthma Control Questionnaire (ACQ)-5 On-treatment Score: The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitatio... | false | CHILD, ADULT, OLDER_ADULT | null |
NCT02491671 | Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection | Prospective, Multicenter, Open-Label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak After Lung Resection in High-risk Patients, Applying HEMOPATCH® | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | COMPLETED | 2015-11-24 | 2019-06-30 | INTERVENTIONAL | PHASE3 | 260 | Prolonged Air Leak, Lung Resection | Prevention PAL Prolonged Air Leak (PAL), Lung Resection, Thoracic Surgery, Post-operative Thoracic Air Leak | Inclusion Criteria:
* Scheduled anatomical lung resection indicated for any non-infectious disease (excluding Pneumonectomy)
* Patients classified in class D according estimated risk of PAL
* Age between 18 and 80 years
Exclusion Criteria:
* Those patients that according to Investigator assessment are not going to t... | ALL | 18 Years | 80 Years | The effectiveness of tissue sealants to prevent Prolonged Air Leak (PAL) after lung resection procedures remains unproved. The investigators hypothesize that one of the main reasons for that is the heterogeneity of previously studied populations. Since currently the risk of postoperative PAL can be scored with a reason... | 1 | Prot_SAP_000.pdf | https://cdn.clinicaltrials.gov/large-docs/71/NCT02491671/Prot_SAP_000.pdf | Prolonged air leak | Pulmonology | Inclusion Criteria:
- Age between 18 and 80 years
- Patients who are going to undergo scheduled anatomical lung resection (excluding pneumonectomy).
- Patients class D on the air leak risk scale.
Exclusion Criteria:
- Those who in the judgment of the investigator are not in an adequate situation to tolerate the proced... | null | 2019-06-30 | PARALLEL | PREVENTION | NONE | Experimental group; Control group | DEVICE: Hemopatch (); PROCEDURE: standard preventive measures () | Number of Participants With Prolonged Air Leak (PAL): Prevalence of Prolonged Air Leak (PAL) measured as binary variable (YES/NO) and recorded, from day of surgery to the fifth postoperative day, in the study questionnaire. The occurrence of the outcome will be recorded if air leak exists 5 days or more after surgery (... | Duration of Air Leaks: Measured as continuous variable (days) and recorded, from day of surgery to the day of withdraw the chest tube. (standardized criteria for pulling out chest drainage/s will be agreed among investigators) (Check everyday from day of surgery up to 38 days post-operative at maximum); Number of Parti... | false | ADULT, OLDER_ADULT | null |
NCT04186819 | Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. | A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer | Blue Earth Diagnostics | COMPLETED | 2020-03-02 | 2021-06-21 | INTERVENTIONAL | PHASE3 | 356 | Prostate Cancer | Primary Prostate Cancer, Diagnostic, Prostate Specific Membrane Antigen (PSMA), Positron Emission Tomography (PET) Scan | Inclusion Criteria:
1. Patient is male and aged \>18 years old.
2. Histologically confirmed adenocarcinoma of the prostate.
3. Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND).
Exclusion Criteria:
1. Patients who are planned to have an x-ray contrast agent or other PET... | MALE | 18 Years | null | A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer. | 1 | Prot_000.pdf | https://cdn.clinicaltrials.gov/large-docs/19/NCT04186819/Prot_000.pdf | Prostate cancer | Oncology | Inclusion Criteria:
- Patient willing to provide signed informed consent and willing to comply with all required study schedule events, where safe and feasible.
- Patient is male and aged >18 years old.
- Histologically confirmed adenocarcinoma of the prostate.
- Candidate for RP with PLND and scheduled to undergo the ... | null | 2021-06-21 | SINGLE_GROUP | DIAGNOSTIC | NONE | Patients | DRUG: rhPSMA-7.3 (18F) Injection (Radioligand for PET CT scanning); DIAGNOSTIC_TEST: Positron Emission Tomography scan (imaging test with radioligand) | Specificity: The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND. (Convent... | Verified Detection Rate (VDR) for M1 Lesions - Percentage of Patients in Whom rhPSMA-7.3 (18F) Imaging Detected at Least One Verified M1 Metastasis, as Determined by Central BIE and Confirmed by SoT (Biopsy or Imaging) (Objective 1): This was a key secondary endpoint in this study and included patients in the EEP with ... | false | ADULT, OLDER_ADULT | Main objective is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central blinded image evaluation \[BIE\]) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during radical prostatectomy (RP... |
NCT04115319 | A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. | A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | COMPLETED | 2019-11-21 | 2022-12-30 | INTERVENTIONAL | PHASE3 | 305 | Schizophrenia | schizophrenia | Inclusion criteria:
The main inclusion criteria include, but are not limited to the following:
* Male or female participant between 18 to 65 years of age (inclusive) at the time of consent.
* Participant meets DSM-5 criteria for a diagnosis of schizophrenia as established by clinical interview at screening (using the... | ALL | 18 Years | 65 Years | A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia.
This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers ... | 1 | Prot_000.pdf | https://cdn.clinicaltrials.gov/large-docs/19/NCT04115319/Prot_000.pdf | Schizophrenia | Psychiatry | Inclusion Criteria:
- Subject must give written informed consent and privacy authorization prior to participation in the study. Separate consent will be obtained from a caregiver or legal guardian if required by local law.
- In the Investigator’s opinion, the subject is appropriate for this study and is willing and abl... | null | 2022-12-30 | PARALLEL | TREATMENT | QUADRUPLE | SEP363856; quetiapine XR | DRUG: SEP363856 (SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule); DRUG: quetiapine XR (quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule) | Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation: An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Untoward medical occurrences that occured after first... | null | false | ADULT, OLDER_ADULT | This is a 52-week, multicenter, randomized, double-blind, parallel-group, flexible-dose study designed to evaluate the long-term safety and tolerability of SEP-363856 (50 to 100 mg/day) compared with quetiapine XR (400 to 800 mg/day) in clinically stable adult participants with schizophrenia. This study is projected to... |
NCT03129100 | A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis | A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis | Eli Lilly and Company | COMPLETED | 2017-05-09 | 2021-05-27 | INTERVENTIONAL | PHASE3 | 773 | Axial Spondyloarthritis | null | Inclusion Criteria:
* Have completed the final study visit in Study RHBV (NCT02696785), RHBW (NCT02696798), or RHBX (NCT02757352).
(Note: Participants from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor \[TNF\] inhibitor).
* Must agree to use a reli... | ALL | 18 Years | null | The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis. | 1 | Prot_000.pdf | https://cdn.clinicaltrials.gov/large-docs/00/NCT03129100/Prot_000.pdf | Axial spondyloarthritis | Rheumatology | Inclusion Criteria:
- Have completed the final study visit in Study RHBV, RHBW, or RHBX. (Note: Patients from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a TNF inhibitor).
- Must agree to use a reliable method of birth control.
- If the patient is male, the patient must ag... | null | 2020-05-26 | PARALLEL | TREATMENT | TRIPLE | Ixekizumab (IXE) 80Q4W; Ixekizumab (IXE) 80Q2W; Placebo | DRUG: Ixekizumab (Administered SC); DRUG: Placebo (Administered SC) | Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment): A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2.
ASDAS is a composite index to assess disease activity in AS. The parameters us... | Percentage of Participants Who do Not Experience a Flare: A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2.
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sens... | false | ADULT, OLDER_ADULT | null |
NCT03198507 | ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator | A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection | RedHill Biopharma Limited | COMPLETED | 2017-06-18 | 2018-12-13 | INTERVENTIONAL | PHASE3 | 455 | Helicobacter Pylori Infection, Dyspepsia | null | Inclusion Criteria:
1. Be ages 18 - 70, inclusive; non-Asian males and females (This population has been demonstrated to have significantly elevated omeprazole levels as per the prescriber information for other omeprazole products). A person having origins in any of the original peoples of the Far East, Southeast Asia... | ALL | 18 Years | 70 Years | The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator. | 1 | Prot_002.pdf | https://cdn.clinicaltrials.gov/large-docs/07/NCT03198507/Prot_002.pdf | Helicobacter pylori infection | Pulmonology | Inclusion Criteria:
- Be ages 18 – 70, inclusive; non-Asian males and females (This population has been demonstrated to have significantly elevated omeprazole levels as per the prescriber information for other omeprazole products). A person having origins in any of the original peoples of the Far East, Southeast Asia, ... | ERADICATE Hp2 | 2018-10-24 | PARALLEL | TREATMENT | TRIPLE | RHB-105; Active Comparator | DRUG: RHB-105 (The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:
* Rifabutin 150 mg
* Amoxicillin 3000 mg
* Omeprazole 120 mg
One 50mg Riboflavin tablet to be taken once daily to maintain the blind.... | Number of Participants With Eradication of H. Pylori: Eradication of H. pylori confirmed via 13C Urea Breath Test (UBT) testing. Subjects with negative test results (eradication of H. pylori) were considered treatment successes. Subjects who tested positive for H. pylori infection (no eradication) were considered treat... | Number of Participants With H. Pylori Cultures That Presented Antibiotic Resistance and Susceptibility: The primary endpoint was summarized within subgroups formed by the presence of H. pylori susceptibility and resistance to amoxicillin, clarithromycin, metronidazole, and rifabutin from H. pylori cultures from samples... | false | ADULT, OLDER_ADULT | This is a, randomized, double blind, active comparator-controlled study of RHB-105 in adult subjects complaining of epigastric discomfort that have been screened and found to be positive for H. pylori infection via 13C UBT and gastric biopsy.
The biopsy samples will also be used to conduct H. pylori antibiotic suscept... |
NCT03050307 | Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection | A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection | Takeda | COMPLETED | 2017-04-17 | 2020-05-26 | INTERVENTIONAL | PHASE3 | 234 | Gastric Ulcer | Drug therapy | Inclusion Criteria:
1\. Has endoscopic evidence of active gastric ulcer(s) (i.e. mucosal defects with white coating \[including cases associated with blood coagula as long as there is no active bleeding\]) measuring 5 mm or larger in longest diameter within 14 days prior to randomization.
Exclusion Criteria:
1. Has ... | ALL | 18 Years | null | The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer. | 1 | Prot_000.pdf | https://cdn.clinicaltrials.gov/large-docs/07/NCT03050307/Prot_000.pdf | Gastric ulcer | Gastroenterology | Inclusion Criteria:
- In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements.
- The subject or, when applicable, the subject’s legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to ... | null | 2020-02-19 | PARALLEL | TREATMENT | QUADRUPLE | TAK-438 20 mg; Lansoprazole 30 mg | DRUG: TAK-438 (TAK-438 tablets); DRUG: Lansoprazole (Lansoprazole capsules); DRUG: TAK-438 Placebo (TAK-438 placebo-matching tablets); DRUG: Lansoprazole Placebo (Lansoprazole placebo-matching capsules); DRUG: Bismuth-Containing Quadruple Therapy (1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citr... | Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8: Endoscopic healing was defined as the disappearance of all white coats associated with GUs confirmed endoscopically. (Week 4 or 8) | Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 8 Weeks of Treatment: HP infection status was determined by 13C-UBT. The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a cent... | false | ADULT, OLDER_ADULT | The drug being tested in this study is called TAK-438. TAK-438 is being tested to treat people who have stomach ulcers and also may or may not have Helicobacter pylori (HP) infection. This study will look at stomach ulcer healing and also the elimination of HP in people who take TAK-438 versus lansoprazole.
The study ... |
NCT03084471 | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. | An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. | AstraZeneca | COMPLETED | 2017-06-05 | 2022-12-16 | INTERVENTIONAL | PHASE3 | 867 | Advanced Solid Malignancies | Programmed death ligand 1 (PD-L1), Cytotoxic T-lymphocyte antigen-4 (CTLA-4), Durvalumab in combination with tremelimumab | Inclusion criteria:
1. Must have a life expectancy of at least 12 weeks.
2. Age ≥18 years at the time of screening. For patients aged \<20 years and enrolled in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative
3. Capable of giving signed informed co... | ALL | 18 Years | 130 Years | To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors. | 1 | Prot_002.pdf | https://cdn.clinicaltrials.gov/large-docs/71/NCT03084471/Prot_002.pdf | Malignant neoplasm of solid organ | Oncology | Inclusion Criteria:
- Must have a life expectancy of at least 12 weeks.
- Age ≥18 years at the time of screening. For patients aged <20 years and enrolled in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative
- Capable of giving signed informed consent... | STRONG | 2020-03-31 | SEQUENTIAL | TREATMENT | NONE | Combination therapy; Monotherapy | BIOLOGICAL: MEDI4736 (Durvalumab) (A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).); BIOLOGICAL: MEDI4736 (Durvalumab) + Tremelimumab (Durvalumab: A h... | Number of Participants With Adverse Events of Special Interest (AESIs): Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of AESIs were assessed. AESIs included events with a potential inflammatory or immune-mediated mechanism that required interventions such as steroids, immunosu... | Overall Survival: Overall survival was defined as the time from the first date of treatment until death due to any cause. (From screening to final data cutoff (maximum up to 4 years) following date of first patient treatment initiation.); Number of Participants With Adverse Events: Incidence, severity, nature, seriousn... | false | ADULT, OLDER_ADULT | This is an open-label, multi-center, study to determine the short and long term safety of fixed doses of durvalumab 1500 mg + tremelimumab 75 mg combination therapy or durvalumab 1500 mg monotherapy in patients with advanced solid malignancies. This study is modular in design, one or more of the modules will be opened ... |
NCT00118209 | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma | Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas | Alliance for Clinical Trials in Oncology | COMPLETED | 2005-05 | 2021-11-15 | INTERVENTIONAL | PHASE3 | 524 | Large B Cell Lymphoma | null | 1. Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease.
* Stage I primary mediastinal (thymic) DLBCL is also eligible.
* Patients with an underlying low-grade lymphoma, such as a transformed lymphoma or low-grade lymphoma in the bone marrow, are not eligible.
* Diagnosis should be b... | ALL | 18 Years | null | This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting... | 1 | Prot_SAP_000.pdf | https://cdn.clinicaltrials.gov/large-docs/09/NCT00118209/Prot_SAP_000.pdf | Diffuse large B-cell lymphoma | Oncology | Inclusion Criteria:
- Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease.
- Stage I primary mediastinal (thymic) DLBCL is also eligible.
- Diagnosis should be based on an adequate tissue sample, including open biopsy or core needle biopsy.
- Patients must have one of the following WHO [21] c... | null | 2017-10 | PARALLEL | TREATMENT | NONE | Arm A - R-CHOP; Arm B - DA-EPOCH-R | BIOLOGICAL: rituximab (IV); DRUG: cyclophosphamide (IV); DRUG: doxorubicin (IV or CIVI); DRUG: vincristine (IV or CIVI); DRUG: prednisone (oral); DRUG: etoposide (CIVI); DRUG: filgrastim (IV); DRUG: pegfilgrastim (IV) | Progression-Free Survival Rate at 2 and 5 Years: Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse\>
* ≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs ... | Response Rate: The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response) (Up to 5 years post-registration); Overall Survival Rate at 2 and 5 Years: Overall survival is defined as the time from randomization to death due to any cause. The overall survi... | false | ADULT, OLDER_ADULT | PRIMARY OBJECTIVES:
I. To compare the event-free survival of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone (R-CHOP) versus dose-adjusted (DA-) etoposide, prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, and rituximab (EPOCH-R) chemotherapy in untre... |
NCT02480764 | Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension | A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension | Takeda | COMPLETED | 2015-08-27 | 2017-10-13 | INTERVENTIONAL | PHASE3 | 612 | Essential Hypertension | Drug therapy | Inclusion Criteria:
1. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure (SBP) ≥150 and ≤180 mm Hg on Day 1; or the participant has not received antihypertensive treatment within 28 days prior to Screening and has a mean sitting clinic SBP ≥150 and ≤180 mm Hg a... | ALL | 18 Years | null | The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension. | 1 | Prot_000.pdf | https://cdn.clinicaltrials.gov/large-docs/64/NCT02480764/Prot_000.pdf | Essential hypertension | Cardiology | Inclusion Criteria:
- The subject is treated with antihypertensive therapy and has a post-washout mean sitting clinic SBP ≥150 and ≤180 mm Hg on Day 1; or the subject has not received antihypertensive treatment within 28 days prior to Screening and has a mean sitting clinic SBP ≥150 and ≤180 mm Hg at the Screening Visi... | null | 2017-09-22 | PARALLEL | TREATMENT | QUADRUPLE | Azilsartan medoxomil 40 mg; Azilsartan medoxomil 80 mg; Valsartan 160 mg | DRUG: Azilsartan medoxomil (Azilsartan medoxomil tablets); DRUG: Valsartan (Valsartan 80 mg capsules); DRUG: Azilsartan medoxomil Placebo (Azilsartan medoxomil placebo-matching tablets); DRUG: Valsartan Placebo (Valsartan placebo-matching capsules) | Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP): The change in trough clinic sitting SBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting SBP measurements. Blood pressure was measured using a validated, automated device a... | Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure (DBP): The change in trough clinic sitting DBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting DBP measurements. Blood pressure was measured using a validated, automated device ... | false | ADULT, OLDER_ADULT | The drug being tested in this study is called TAK-491 (azilsartan medoxomil). Azilsartan medoxomil is being tested to treat Chinese people who have essential hypertension. This study will look at change in blood pressure after 8 weeks of treatment in people who take azilsartan medoxomil compared to people who take vals... |
ProtocolEC
A protocol-derived benchmark for complete clinical-trial eligibility-criteria (EC) generation.
ProtocolEC pairs each of 4,302 completed Phase III trials (22 therapeutic areas) with (i) its ClinicalTrials.gov registry metadata and registry EC, and (ii) a more complete EC set extracted from the trial's protocol PDF. Protocol EC contain roughly twice the criteria and words of the registry EC. Splits are 80/10/10, stratified by therapeutic area.
| Split | Trials |
|---|---|
| train | 3,443 |
| validation | 429 |
| test | 430 |
Task
Given a trial's features (title, summary, phase, conditions, interventions, demographics), generate
the complete, protocol-level eligibility criteria (complete eligibility criteria). The registry
EC (Eligibility Criteria (registry)) is a compressed public summary and serves as a baseline /
comparison, not the target.
from datasets import load_dataset
ds = load_dataset("<your-org>/protocolec")
ex = ds["test"][0]
ex["Eligibility Criteria (registry)"] # compressed registry summary (baseline)
ex["complete eligibility criteria"] # protocol-extracted GOLD target
Columns (35)
- Identifier:
NCT ID - Target (gold):
complete eligibility criteria— protocol-extracted complete EC - Registry EC (baseline):
Eligibility Criteria (registry) - Trial features (input):
Brief Title,Official Title,Brief Summary,Detailed Description,Phases,Conditions,Interventions,Intervention Model,Primary Purpose,Masking,Arms,Study Type,Keywords,SNOMED CT,primary_therapeutic_area,Enrollment Count,Overall Status,Organization,Acronym,Primary Outcomes,Secondary Outcomes,Start Date,Completion Date,Primary Completion Date - Demographics:
Sex,Minimum Age,Maximum Age,Standard Ages,Healthy Volunteers - Provenance:
Protocol Doc Count,Protocol Filenames,Protocol URLs
Protocol PDFs
The source protocol PDFs are not redistributed here. Each row carries Protocol URLs
(ClinicalTrials.gov CDN links), from which the PDFs can be downloaded directly if needed.
Construction (summary)
Phase III trials with an attached protocol PDF were retrieved from the ClinicalTrials.gov v2 API; the EC section of each PDF was localized with a deterministic three-stage locator; EC were extracted verbatim with an LLM extractor; multiple protocol documents per trial were merged; each trial was assigned a primary therapeutic area; and a blinded three-judge audit validated coverage/enrichment against the registry EC. See the paper for full details.
License & ethics
Released for non-commercial research use (CC BY-NC 4.0). Source records are U.S. public-domain ClinicalTrials.gov content. The data contains no patient-level records or identifiable health information: eligibility criteria describe general study-population requirements, not individuals.
Citation
@article{protocolec,
title = {Beyond the Registry: A Protocol-Derived Dataset and Embedding-Guided Method for Complete Clinical Trial Eligibility Criteria Generation},
author = {<authors>},
year = {2026}
}
- Downloads last month
- 48